Tiedemann Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Tiedemann Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-917	Closed	-$82K	–	306
2020 Q1	$82K	Buy	+917	New	+$56.5K	0.01%	285

Other funds holding INO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Tiedemann Advisors's INO Position: Q2 2020 in Review

Tiedemann Advisors sold out of Inovio Pharmaceuticals (INO) in Q2 2020, closing a stake of 917 shares — an estimated $82K sold.

Tiedemann Advisors first reported a position in INO in Q1 2020 and held it in 1 quarter. The position peaked at $82K in Q1 2020. 214 funds tracked by Wall St. Rank hold INO as of Q2 2020.

Tiedemann Advisors reported no remaining Inovio Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Tiedemann Advisors sold 917 Inovio Pharmaceuticals shares in Q2 2020, an estimated $82K.
Tiedemann Advisors first reported a position in Inovio Pharmaceuticals in Q1 2020 and held it in 1 quarter.
Tiedemann Advisors's Inovio Pharmaceuticals position peaked at $82K in Q1 2020.
214 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2020.

Based on Tiedemann Advisors's 13F filing for Q2 2020, filed 5 Aug 2020.